FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT

Ann Oncol. 2001 Apr;12(4):479-86. doi: 10.1023/a:1011111322376.

Abstract

Background: The purpose was the comparison of positron emission tomography using F-18-fluorodeoxy-glucose (FDG-PET) and spiral thoracic CT to detect pulmonary metastases from malignant primary osseous tumors.

Patients and methods: In 71 patients with histologically confirmed malignant primary bone tumors (32 osteosarcomas, 39 Ewing's sarcomas) 111 FDG-PET examinations were evaluated with regard to pulmonary/pleural metastases in comparison with spiral thoracic CT. Reference methods were the clinical follow-ups for 6-64 months (median 20 months) or a histopathologic analysis.

Results: In 16 patients (23%) reference methods revealed a pulmonary/pleural metastatic disease. FDG-PET had a sensitivity of 0.50, a specificity of 0.98, and an accuracy of 0.87 on a patient based analysis. Comparable values for spiral CT were 0.75, 1.00, and 0.94. It was shown that no patient who had a true positive FDG-PET had a false negative CT scan, nor was a pulmonary metastases detected earlier by FDG-PET than by spiral CT.

Conclusions: There seems to be a superiority of spiral CT in the detection of pulmonary metastases from malignant primary bone tumors as compared with FDG-PET. Therefore, at present a negative FDG-PET cannot be recommended to exclude lung metastases. However, as specificity of FDG-PET is high, a positive FDG-PET result can be used to confirm abnormalities seen on thoracic CT scans as metastatic.

Publication types

  • Comparative Study

MeSH terms

  • Adolescent
  • Adult
  • Bone and Bones / diagnostic imaging
  • Bone and Bones / pathology*
  • Child
  • Child, Preschool
  • Female
  • Fluorodeoxyglucose F18*
  • Humans
  • Lung Neoplasms / diagnostic imaging*
  • Lung Neoplasms / secondary
  • Male
  • Osteosarcoma / diagnosis
  • Osteosarcoma / diagnostic imaging*
  • Osteosarcoma / secondary
  • Radiography, Thoracic
  • Radiopharmaceuticals*
  • Retrospective Studies
  • Sarcoma, Ewing / diagnostic imaging*
  • Sarcoma, Ewing / secondary
  • Sensitivity and Specificity
  • Tomography, Emission-Computed / methods

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18